本帖最后由 老马 于 2012-1-13 21:20 编辑 - `$ \! v* c A2 N7 q( g6 ^ ~ x
$ M7 M0 z y& L, j+ `6 h爱必妥和阿瓦斯丁的比较
: c" `, N" O& g: n% V' Q0 `" _
- O7 J0 f% j" `3 I
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 q% T$ ~9 P# Q# u9 P) V; Q8 G
6 w9 o; ?$ T& i0 d* ]# Z
4 b9 b% k# D/ X- r# N- r
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
4 a% ^7 W3 f% P& c==================================================
" H0 T0 X3 }/ e( TOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)- l* T( e# F9 Q1 _ n# s' x. }
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.0 w* K, I& J' G; ^0 Q( Z
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( I: @2 i5 B( _
|